Notícias e Atividades da Corvus Pharmaceuticals
Presença
Corvus Pharmaceuticals é uma empresa listada sob o símbolo CRVS (US).
Executivos
Veja o organograma con seus 13 executivos principais
Biografias mais buscadas da Corvus Pharmaceuticals
- Richard Miller, Chief Executive Officer and Chairman of the Board
- Scott Morrison, Director
- Linda Grais, Director
Recentes movimentos de executivos em Corvus Pharmaceuticals
- Richard Van Den Broek, ingressou na Companhia como Director (Notícia publicada em 10 de abril de 2025).
Criar um alerta
para seguir os movimentos de executivos da Corvus Pharmaceuticals.
Farmacêutica
Corvus Pharmaceuticals possui 1.833 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Eli Lilly (Estados Unidos).
Popular M&A news in Farmacêutica
- Imbria Pharmaceuticals acaba de anunciar uma arrecadação de fundos de 58 milhões de dólares. (publicado em 10 de abril de 2025).
- Clario adquiriu NRx Pharmaceuticals (publicado em 18 de março de 2025).
- Knight Therapeutics has announced the acquisition of Paladin Labs (publicado em 12 de março de 2025).
Outros contatos sugeridos na indústria do Farmacêutica
Notícias
Últimos comunicados de imprensa de Corvus Pharmaceuticals
- Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis | Corvus Pharmaceuticals
- Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024 | Corvus Pharmaceuticals
- Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity | Corvus Pharmaceuticals
- Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis | Corvus Pharmaceuticals
- Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer | Corvus Pharmaceuticals
- Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results | Corvus Pharmaceuticals
- Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024 | Corvus Pharmaceuticals
- Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma | Corvus Pharmaceuticals
- Corvus Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference | Corvus Pharmaceuticals
- Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results | Corvus Pharmaceuticals
- View more press releases Close
Redes sociais sobre Corvus Pharmaceuticals
- Corvus Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
- Corvus Pharmaceuticals na LinkedIn, Twitter e YouTube
